3-(Tetraacetyl glucopyranos-2-yl)-1-(2-chloroethyl)-1-nitrosourea, an antitumor agent with modified bone marrow toxicity.
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D001853:Bone Marrow / Q000187:drug effects*; D002330:Carmustine / Q000009:adverse effects / Q000627:therapeutic use; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use; D004273:DNA, Neoplasm / Q000096:biosynthesis; D005753:Gastric Mucosa / Q000378:metabolism; D005947:Glucose; D007413:Intestinal Mucosa / Q000378:metabolism; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D009243:NAD / Q000037:antagonists & inhibitors; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D013311:Streptozocin / Q000009:adverse effects / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D013997:Time Factors
D000970:Antineoplastic Agents; D001786:Blood Glucose; D003510:Cyclohexanes; D004273:DNA, Neoplasm; D009607:Nitrosourea Compounds; D009243:NAD; D013311:Streptozocin; D005947:Glucose; D002330:Carmustine